Hanmi Pharmaceutical announced on the 25th that its consolidated operating profit for the second quarter of this year was 60.4 billion won, marking a 4% increase compared to the same period last year.
During the same period, sales decreased by 4.5% to 361.3 billion won, and net profit fell by 8.6% to 43 billion won.
In the first half of this year, the cumulative research and development (R&D) expense was 105.7 billion won, accounting for 14.4% of total sales.
※ This article has been translated by AI. Share your feedback here.